Cure for Alzheimer’s Disease

Abstract

Alzheimer's disease (AD) is progressively being recognized amongst the most vital medical and social issues in older individuals in industrialized and non-industrialized countries. To date, just symptomatic medications exist for this disease, all attempting to offset the neurotransmitter disturbance. Recently, cholinesterase inhibitors (CIs) are now accessible and have been authorized for the treatment of mild to moderate AD. Further remedial alternative available for moderate to severe AD is memantine, an N-methyl-D-aspartate receptor noncompetitive antagonist. Treatments equipped for halting or slightly adjusting the course of AD are known as "ailment changing" medications, and are still under extensive examination. To obstruct the movement of the ailment, they need to interfere with the pathogenic steps in charge of the clinical symptoms, including the disposition of extracellular amyloid β plaques and intracellular neurofibrillary tangle formation, irritation, oxidative damage, iron deregulation and cholesterol metabolism. This paper discusses the cure for Alzheimer's disease, the current symptomatic treatments and the treatment of mild and moderate Alzheimer's disease and the functions of its drugs.

Mitochondria are an Important Target in the Search for new Drugs for the Treatment of Alzheimer′s Disease and Senile Dementia

“…Старение является основным фактором риска спорадических форм различных нейродегенеративных заболеваний, в том числе и болезни Альцгеймера (БА). С возрастом вероятность развития БА значительно увеличивается, в 65-69 лет около 2% людей страдают БА, а после 90 лет -уже 25% [1]. Поэтому очевидно, что механизмы нарушения когнитивных функций при нормальном старении и при развитии нейродегенеративных заболеваний могут иметь общие черты.…”

A Meta-Analysis Study on Alzheimer’s Disease

“…To address this deficiency, doctors try to increase acetylcholine by preventing its degradation. Increased levels of this white crystalline compound in the brain help to improve cognition and memory impairment, both of which are symptoms of Alzheimer's disease [5] The Food and Drug Administration has approved four cholinesterase inhibitors to treat Alzheimer's disease in mild, moderate, and severe cases. These inhibitors are used to treat symptoms of Alzheimer's disease that involve thinking, judgment, language, memory, and other thought processes.…”

Plants‐Derived Neuroprotective Agents: Cutting the Cycle of Cell Death through Multiple Mechanisms

“…As the world population continues to age in parallel with economic development, the number of people with NDs and the associated dementia also continues to increase [ 20 ]. This increase has in turn prompted an enormous increment in research interest and efforts on the discovery of new therapeutic agents for primary, auxiliary, or tertiary prevention of these diseases [ 21 ].…”

“…There is no cure for NDs and all current therapeutic interventions are aimed at managing the symptoms and improvement in the quality of life in patients. Therapies for AD, PD, and other NDs provide symptomatic improvement by several mechanisms such as restoring the levels of neurotransmitters or controlling the metabolism of neurotransmitters involved in the diseases [ 1 , 12 , 13 , 21 ]. With the abounding evidences that the central cholinergic system plays a key role in the retrieval and storage of memory items in the CNS of mammals [ 25 – 27 ], some current therapeutic strategies are aimed at boosting the endogenous level of ACh in order to enhance the cholinergic deficits [ 80 ].…”